Two-thirds of differentiated thyroid cancer (DTC) patients with distant metastases would be
classified as radioactive iodine-refractory (RAIR-DTC), evolving into a poor outcome. Recent …

Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence
has been rising rapidly over the past 10 years. Although most patients with this disease have …

Thyroid cancer typically has a good outcome following standard treatments, which include
surgery, radioactive iodine ablation for differentiated tumours and treatment with thyrotropine …

Differentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally
an indolent tumor, treated effectively with surgery, radioactive iodine, and thyroid-stimulating …

Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account> 90% of
thyroid cancer (TC)[papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%] …

Although generally the prognosis of differentiated thyroid carcinoma (DTC) is good,
approximately 5% of people are likely to develop metastases which fail to respond to …

Opinion statement With a growing understanding of the biologic drivers of different thyroid
cancers, there is an ongoing revolution in the treatment of aggressive and advanced …

Advanced differentiated thyroid cancer (DTC), defined by clinical characteristics including
gross extrathyroidal invasion, distant metastases, radioiodine (RAI) resistance, and avidity …

Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

Differentiated thyroid carcinoma (DTC) accounts for more than 90% of new thyroid cancer
diagnoses, and includes papillary, follicular and Hürthle cell carcinoma. The prognosis for …